Javier Suárez1, Gabriel Marín2, Ruth Vera3, Begoña Oronoz2, Fabiola Oteiza2, Elena Mata3. 1. Department of General Surgery, Coloproctology Unit, Complejo Hospitalario de Navarra, c/ Irunlarrea 3, 31008, Pamplona, Spain. fj.suarez.alecha@cfnavarra.es. 2. Department of General Surgery, Coloproctology Unit, Complejo Hospitalario de Navarra, c/ Irunlarrea 3, 31008, Pamplona, Spain. 3. Department of Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain.
Abstract
BACKGROUND: The aim of this study was to evaluate the rate of complications from the primary tumour (CPT) requiring surgical or endoscopic intervention during chemotherapy treatment in patients with incurable synchronous stage IV colorectal cancer, the possibility of predicting such complications and their influence on survival. METHODS: One hundred and twenty-five patients were initially treated with chemotherapy. Patients were grouped on the basis of appearance or not of CPT. We assessed the relation between age, gender, carcinoembryonic antigen (CEA) level, primary tumour location, alkaline phosphatase level, unilobar or bilobar liver involvement, presence of peritoneal carcinomatosis, the number of sites of metastatic disease, the addition of target therapies to chemotherapy, the ability to traverse the tumour with an endoscope and the appearance of complications due to the primary tumour and overall survival. RESULTS: Mean age was 64.9 years, and 89 patients were men. Over a mean of 234 days, 25 patients (20 %) developed a CPT. Eighteen patients required surgery, and seven were treated exclusively by an endoscopic procedure. Mean survival was 15.8 months. We found a statistically relevant correlation between the inability to traverse the tumour with an endoscope and the occurrence of a CPT. There was no statistical differences in survival between both groups, but patients receiving target therapies had better survival. CONCLUSION: Twenty percent of patients will suffer a CPT during chemotherapy treatment. The inability to pass the tumour with an endoscope can predict the CPT. Survival was only related to the addition of target therapies to chemotherapy.
BACKGROUND: The aim of this study was to evaluate the rate of complications from the primary tumour (CPT) requiring surgical or endoscopic intervention during chemotherapy treatment in patients with incurable synchronous stage IV colorectal cancer, the possibility of predicting such complications and their influence on survival. METHODS: One hundred and twenty-five patients were initially treated with chemotherapy. Patients were grouped on the basis of appearance or not of CPT. We assessed the relation between age, gender, carcinoembryonic antigen (CEA) level, primary tumour location, alkaline phosphatase level, unilobar or bilobar liver involvement, presence of peritoneal carcinomatosis, the number of sites of metastatic disease, the addition of target therapies to chemotherapy, the ability to traverse the tumour with an endoscope and the appearance of complications due to the primary tumour and overall survival. RESULTS: Mean age was 64.9 years, and 89 patients were men. Over a mean of 234 days, 25 patients (20 %) developed a CPT. Eighteen patients required surgery, and seven were treated exclusively by an endoscopic procedure. Mean survival was 15.8 months. We found a statistically relevant correlation between the inability to traverse the tumour with an endoscope and the occurrence of a CPT. There was no statistical differences in survival between both groups, but patients receiving target therapies had better survival. CONCLUSION: Twenty percent of patients will suffer a CPT during chemotherapy treatment. The inability to pass the tumour with an endoscope can predict the CPT. Survival was only related to the addition of target therapies to chemotherapy.
Authors: Andrea Muratore; Daria Zorzi; Hedayat Bouzari; Marco Amisano; Paolo Massucco; Elisa Sperti; Lorenzo Capussotti Journal: Ann Surg Oncol Date: 2006-11-14 Impact factor: 5.344
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Laurence E McCahill; Greg Yothers; Saima Sharif; Nicholas J Petrelli; Lily Lau Lai; Naftali Bechar; Jeffrey K Giguere; Shaker R Dakhil; Louis Fehrenbacher; Samia H Lopa; Lawrence D Wagman; Michael J O'Connell; Norman Wolmark Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Sabine Venderbosch; Johannes H de Wilt; Steven Teerenstra; Olaf J Loosveld; Aart van Bochove; Harm A Sinnige; Geert-Jan M Creemers; Margot E Tesselaar; Linda Mol; Cornelis J A Punt; Miriam Koopman Journal: Ann Surg Oncol Date: 2011-08-06 Impact factor: 5.344
Authors: Winson J Tan; Sujata Patil; Jose G Guillem; Philip B Paty; Martin R Weiser; Garrett M Nash; J Joshua Smith; Emmanouil P Pappou; Iris H Wei; Julio Garcia-Aguilar Journal: Dis Colon Rectum Date: 2021-01 Impact factor: 4.412